ForteBio Launches Dip and Read™ Anti-Human Fab-CH1 Biosensor to Accelerate Human Biotherapeutic Drug Development

The Associated Press

PORT WASHINGTON, N.Y.--(BUSINESS WIRE)--Jan 9, 2013--ForteBio, a division of Pall Life Sciences and a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, today announced the launch of its Dip and Read Anti-Human Fab-CH1 biosensor. The new biosensor enables an easy and rapid method for quantitation and kinetic characterization of human Fab, F(ab')2 and IgG – critical processes in drug discovery. Dip and Read biosensors are designed for use on ForteBio's Octet® and BLItz™ instrumentation systems.

"The detection and characterization of human IgG is of paramount importance to research scientists," said Christopher Silva, the ForteBio division's vice president of marketing. "However, traditional approaches to quantitation and kinetic characterization have been cumbersome, slow and expensive. Our new Anti-Human Fab-CH1 biosensor carries the popular CaptureSelect® IgG-CH1 ligand from BAC BV, a company that provides affinity tools widely used in purification of antibodies and antibody fragments. The new biosensor offers researchers unparalleled ease of use and time-to-result in a wide range of laboratory applications, enabling improved laboratory workflow and cost-efficiency." The Anti-Human Fab-CH1 biosensor consists of a pre-immobilized high-affinity, anti-human CH1 affinity ligand that binds specifically to the CH1 domain of all four human IgG subclasses independent of the type of light chain. Its unique selectivity provides solid coverage of any human IgG derived Fab fragment without interference of notorious product-related contaminants like over-expressed free light chains. The high specificity of the biosensor enables direct analysis of human Fab/F(ab')2/IgG in crude lysates, column eluants, cell lysates and cell culture supernatants, providing a time-saving alternative to traditional analytical methods.

The Octet family of products is based on ForteBio's proprietary Bio-Layer Interferometry (BLI) technology. It incorporates disposable optical Dip and Read biosensors that measure multiple interactions in parallel, without the use of detection agents. For single-sample analysis, ForteBio recently launched its BLItz platform. The new platform revolutionizes the use of label-free protein analysis by making it more accessible and cost-effective for individual bench scientists in biotherapeutic discovery, process development and academic research.

About ForteBio ForteBio is a division of Pall Life Sciences. ForteBio provides analytical systems to accelerate biotherapeutic drug discovery and development. These systems enable real-time, label-free analysis of biomolecular interactions, providing information on affinity, kinetics and concentration. ForteBio's analytical capabilities enable significantly easier, faster and better characterization of drug

candidates, thus providing greater value in drug development applications where existing methods have limitations in throughput, performance and cost. For more information, visit www.fortebio.com.

About Pall Life Sciences Pall Life Sciences, a division of Pall Corporation (NYSE: PLL), provides cutting-edge products and services to meet the demanding needs of customers discovering, developing and producing biotech drugs, vaccines and classic pharmaceuticals. Its membranes and membrane devices optimize detection and sample preparation in the drug research, clinical diagnostics, genomics, and proteomics markets. Pall Life Sciences is a leading provider of separation systems and single-use filtration and purification technologies to pharmaceutical and biotechnology companies to support faster development of new drugs and vaccines that are safer and require less energy and water to produce. Pall Life Sciences' technologies are also used in clinical institutions and the food and beverage industries.

About Pall Corporation Pall Corporation (NYSE: PLL) is a filtration, separation and purification leader providing solutions to meet the critical fluid management needs of customers across the broad spectrum of life sciences and industry. Pall works with customers to advance health, safety and environmentally responsible technologies. The company's engineered products enable process and product innovation and minimize emissions and waste. Pall Corporation is an S&P 500 company serving customers worldwide. Pall has been named a "top green company" by Newsweek magazine. To see how Pall is helping enable a greener, safer, more sustainable future, follow us on Twitter @PallCorporation or visit www.pall.com/green.

Photos/Multimedia Gallery Available:http://www.businesswire.com/multimedia/home/20130109006480/en/ CONTACT: Doug Novarro Pall Corporation Corporate Public Relations 516-801-9944 Doug_novarro@pall.com Follow us on Twitter @pallcorporation or Gemma Milan ForteBio 650-289-6800 Gemma_milan@pall.com KEYWORD: UNITED STATES NORTH AMERICA NEW YORK INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL GENERAL HEALTH SOURCE: Pall Corporation Copyright Business Wire 2013 PUB: 01/09/2013 05:00 PM/DISC: 01/09/2013 05:00 PM http://www.businesswire.com/news/home/20130109006480/

Source URL (retrieved on *04/26/2015 - 9:12am*):
http://www.mdtmag.com/news/2013/01/fortebio-launches-dip-and-read%E2%84%A2-anti-human-fab-ch1-biosensor-accelerate-human-biotherapeutic-drug-development?qt-recent_content=0